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A bs tr ac t
Background
The expression of vascular endothelial growth factor (VEGF) is characteristic of 
differentiated thyroid cancer and is associated with aggressive tumor behavior and 
a poor clinical outcome. Motesanib diphosphate (AMG 706) is a novel oral inhibitor 
of VEGF receptors, platelet-derived growth-factor receptor, and KIT.
Methods
In an open-label, single-group, phase 2 study, we treated 93 patients who had pro-
gressive, locally advanced or metastatic, radioiodine-resistant differentiated thyroid 
cancer with 125 mg of motesanib diphosphate, administered orally once daily. The 
primary end point was an objective response as assessed by an independent radio-
graphic review. Additional end points included the duration of the response, pro-
gression-free survival, safety, and changes in serum thyroglobulin concentration.
Results
Of the 93 patients, 57 (61%) had papillary thyroid carcinoma. The objective re-
sponse rate was 14%. Stable disease was achieved in 67% of the patients, and stable 
disease was maintained for 24 weeks or longer in 35%; 8% had progressive disease 
as the best response. The Kaplan–Meier estimate of the median duration of the 
response was 32 weeks (the lower limit of the 95% confidence interval [CI] was 24; 
the upper limit could not be estimated because of an insufficient number of events); 
the estimate of median progression-free survival was 40 weeks (95% CI, 32 to 50). 
Among the 75 patients in whom thyroglobulin analysis was performed, 81% had 
decreased serum thyroglobulin concentrations during treatment, as compared with 
baseline levels. The most common treatment-related adverse events were diarrhea 
(in 59% of the patients), hypertension (56%), fatigue (46%), and weight loss (40%).
Conclusions
Motesanib diphosphate can induce partial responses in patients with advanced or 
metastatic differentiated thyroid cancer that is progressive. (ClinicalTrials.gov 
number, NCT00121628.)
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Thyroid cancers are classified his-tologically into four groups: papillary, fol-licular, medullary, and undifferentiated or 
anaplastic thyroid carcinomas.1 Papillary and fol-
licular carcinomas (including the Hürthle-cell 
variant) are collectively known as differentiated 
thyroid cancers,1,2 and they account for approxi-
mately 95% of incident cases.3 Initial treatment 
typically involves total thyroidectomy followed by 
long-term administration of levothyroxine at dos-
es that suppress thyrotropin; adjuvant radio-
iodine (131I) is often administered as well.2-4 This 
regimen is usually effective, but the 10-year recur-
rence rate is 20 to 30% among patients who are 
older, among patients with tumors larger than 
4 cm in diameter, and among patients in whom 
the tumor extends beyond the thyroid or in whom 
extensive lymph-node metastases develop.4 There 
is no effective treatment for radioiodine-resistant 
metastatic disease; the 10-year survival rate in 
these cases is less than 15%.5
Increased expression of vascular endothelial 
growth factor (VEGF), a potent angiogenesis 
stimulator, is characteristic of differentiated thy-
roid cancers6,7 and is associated with increased 
growth, progression, and invasiveness of the tu-
mor and with decreased recurrence-free survi-
val.4,8-10 For this reason, an inhibitor of angio-
genesis may be effective when initial therapy 
fails.11 Motesanib diphosphate (Amgen) is an oral 
inhibitor of the tyrosine kinases of VEGF recep-
tors 1, 2, and 3; platelet-derived growth-factor 
receptor; and KIT.12 In a phase 1 study, treatment 
with 125 mg of motesanib diphosphate once 
daily resulted in antitumor activity in patients 
with advanced solid cancers, including five pa-
tients with differentiated thyroid cancer.13 In the 
present study, we investigated the efficacy and 
tolerability of motesanib diphosphate in progres-
sive, locally advanced or metastatic differentiated 
thyroid cancer.
Me thods
Patients
We included in the study adults who had histo-
logically confirmed, locally advanced or meta-
static differentiated thyroid cancer and document-
ed evidence of disease progression (based on two 
sets of radiographic images) according to the Re-
sponse Evaluation Criteria in Solid Tumors 
(RECIST),14 as assessed by the investigator, with-
in 6 months before entry into the study. A rising 
serum thyroglobulin level alone was not suffi-
cient evidence of disease progression before en-
rollment. Other key inclusion criteria were the 
presence of at least one lesion that was defined as 
measurable according to the RECIST guidelines 
and that was not amenable to surgical resection 
or external-beam radiation therapy or was refrac-
tory to radioiodine; the absence of untreated 
brain metastases; an Eastern Cooperative Oncol-
ogy Group performance status score of 0 to 2; 
and adequate hepatic, renal, and cardiac func-
tion. Patients were ineligible if they had ever re-
ceived treatment with VEGF-receptor inhibitors 
or if they had received nonhormonal anticancer 
therapy within 30 days before the start of the 
study. The protocol was approved by each center’s 
independent ethics committee or institutional re-
view board, and all patients provided written in-
formed consent before enrollment.
Study Design and End Points
This phase 2, open-label study involving a cohort 
of patients with differentiated thyroid cancer was 
conducted at 42 centers in 10 countries. A parallel 
cohort included similar patients with metastatic 
medullary thyroid cancer; data from this cohort 
were not included in the analysis reported here. 
The primary end point was an objective response 
according to RECIST, as assessed by a central-
ized, independent review. Additional end points 
included the duration of response, progression-
free survival, the time to response, and overall 
survival; adverse events; pharmacokinetic charac-
teristics; and changes in the serum thyroglobulin 
concentration.
Patients received 125 mg of motesanib diphos-
phate orally once daily for up to 48 weeks or until 
there was evidence of unacceptable toxicity or 
disease progression. Treatment was offered be-
yond 48 weeks in an extension study if a clinical 
benefit was observed. Therapy was withheld if a 
treatment-related grade 3 adverse event that could 
not be controlled with supportive care, any related 
grade 4 adverse event, or symptomatic hyperten-
sion occurred. Treatment could be resumed at a 
dose of 100 mg per day, if toxicity was reduced 
to a grade of 1 or less for nonhematologic tox-
icity or to a grade of 2 or less for hematologic 
toxicity, or at a dose of 75 mg per day after a 
second interruption of treatment that was related 
to toxicity.
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Adverse events were classified according to 
the Medical Dictionary for Regulatory Activities, 
and severity was graded according to the Nation-
al Cancer Institute Common Terminology Crite-
ria for Adverse Events, version 3.0. Patients had 
regular assessments of blood pressure (weekly 
until week 6, then every other week until week 
16, and every 4 weeks thereafter), blood chemi-
cal profiles, blood counts, and urine protein 
levels. Free thyroxine and thyrotropin levels were 
measured at baseline and monthly thereafter.
Assessment of Tumor Response
Computed tomographic or magnetic resonance 
imaging scans of the neck, chest, and abdomen 
were obtained at 8-week intervals and when pro-
gression of the disease was suspected. An objec-
tive response (complete or partial response ac-
cording to RECIST) was assessed by a centralized, 
independent review, with confirmation by repeat 
imaging studies at least 4 weeks later. A bone 
scintigram that showed no new osseous metasta-
ses (as compared with the findings at study entry) 
was also required to define an objective response 
in patients with follicular or Hürthle-cell carci-
noma. The designation of stable disease required 
a single assessment of either stable disease or an 
unconfirmed objective response 47 days or more 
after the first administration of the drug.
Pharmacokinetics
Plasma samples to assess pharmacokinetics were 
collected from nine patients 15 minutes, 30 min-
utes, and 1, 2, 4, 6, 8, and 24 hours after the ad-
ministration of the drug on day 1 of the study. To 
assess trough concentrations of motesanib after 
long-term administration, plasma was collected 
before the daily dose at 4-week intervals during 
the first 24 weeks of the study. Plasma motesanib 
concentrations were measured by means of liquid 
chromatography coupled with tandem mass spec-
troscopy (CEDRA Clinical Research).
Thyroglobulin Analyses and Tumor 
Genotyping
Blood samples were collected at baseline and at 
4-week intervals, and serum thyroglobulin mea-
surements were performed with the use of the 
Access 2 automated immunochemiluminometric 
assay (Beckman Coulter). Intraassay coefficients 
of variation were 3.3%, 1.7%, and 1.9% at 0.76, 
7.0, and 106 ng per milliliter, respectively; inter-
assay coefficients of variation over the 9-month 
period of measurement were 4.8%, 4.7%, and 5.0% 
at 0.75, 7.3, and 106 ng per milliliter, respectively.
Tumor DNA from 33 patients was centrally 
screened for mutations in RET, B-type Raf kinase 
(BRAF), HRAS, KRAS, NRAS, and phosphatidylinos-
itol-3-kinase, catalytic, alpha polypeptide (PIK3CA), and 
for rearrangements of RET-PTC1, RET-PTC3, and 
PAX8-peroxisome proliferator–activated receptor gamma 1 
(PPARγ1). A detailed description of the methods 
is included in the Supplementary Appendix (avail-
able with the full text of this article at www.
nejm.org).
Statistical Analysis
We planned to enroll at least 80 patients to 
achieve a two-sided 95% confidence interval of 
12 to 30% for the rate of an objective response, 
assuming an observed rate of 20%. All patients 
who received one dose or more of motesanib 
diphosphate were included in the efficacy and 
safety analyses. The overall tumor response was 
derived from multiple time-point responses as 
assessed by an independent radiographic review. 
The duration of the tumor response was the in-
terval between the first, subsequently confirmed, 
objective response and evidence of progressive 
disease. The time to the response was the time 
from the first administration of the study drug to 
the initially documented (and subsequently con-
firmed) response. Progression-free survival was 
the time from the first administration of the 
drug to the date of radiographic evidence of dis-
ease progression or death. The duration of the 
response, progression-free survival, and overall 
survival were described with Kaplan−Meier esti-
mates and 95% confidence intervals. The thyro-
globulin analysis subgroup included all patients 
for whom baseline and one or more post-baseline 
measurements of thyroglobulin were available and 
who did not have detectable antithyroglobulin 
antibodies.
Amgen designed the study, in collaboration 
with the study cochairs, Drs. Sherman and 
Schlumberger. The academic authors had com-
plete access to the study data and decided, with 
Amgen’s support, to publish the study. Employ-
ees of Amgen collected and managed the data 
and performed the statistical analysis. An inde-
pendent panel of radiologists from RadPharm, 
a commercial imaging laboratory, reviewed all 
radiographic assessments. Amgen and the study 
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Table 1. Demographic and Baseline Characteristics of the Patients.
Characteristic All Patients (N = 93)
Sex — no. (%)
Female 44 (47)
Male 49 (53)
Age — yr
Median 62
Range 36–81
Race or ethnic group — no. (%)*
White 85 (91)
Asian 4 (4)
Hispanic or Latino 3 (3)
Black 1 (1)
Histologic subtype of differentiated thyroid cancer — no. (%)
Papillary† 57 (61)
Hürthle cell 17 (18)
Follicular 15 (16)
Other‡ 4 (4)
Time from initial diagnosis — yr§
Median 4.4
Range 0.4–21.3
Extent of disease — no. (%)
Locally advanced 1 (1)
Metastatic 92 (99)
No. of sites of disease — no. (%)
1 26 (28)
2 39 (42)
≥3 28 (30)
ECOG performance status — no. (%)¶
0 47 (51)
1 37 (40)
2 9 (10)
Prior therapy for thyroid cancer — no. (%)
Thyroidectomy‖ 93 (100)
Radioiodine therapy
0 Courses 3 (3)
1 Course 14 (15)
2 Courses 35 (38)
≥3 Courses 41 (44)
External-beam radiation therapy
0 Unique sites 40 (43)
1 Unique site 32 (34)
≥2 Unique sites 21 (23)
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cochairs interpreted the data. The manuscript 
was written by the study cochairs, with assistance 
from Complete Healthcare Communications and 
Amgen and with contributions from all of the 
coauthors. The study cochairs attest to the com-
pleteness and accuracy of the data.
R esult s
Patients
Between July 29, 2005, and March 13, 2006, a 
total of 93 patients with differentiated thyroid 
cancer were enrolled in the study. All of the pa-
tients received one dose or more of motesanib 
diphosphate. A total of 32 patients completed 48 
weeks of treatment. The remaining patients dis-
continued the drug because of disease progres-
sion (35 patients), adverse events (12), death (5), 
withdrawal of consent (1), an administrative de-
cision (1), a protocol deviation (1), or the patient’s 
request (6). The median length of treatment for all 
patients was 35 weeks (range, 0.4 to 56), and the 
median follow-up was 50 weeks (range, 1 to 77).
The most common histologic subtype was 
papillary thyroid carcinoma. At study entry, al-
most all of the patients had metastases, usually 
with multiple sites of disease, including lung 
(87%), lymph nodes (72%), and liver (26%). Dis-
ease progression according to RECIST within 
6 months before study day 1 was documented in 
all patients by the investigator. Seventeen percent 
of the patients had previously received systemic 
chemotherapy (Table 1).
Table 1 summarizes the results of tumor geno-
Table 1. (Continued.)
Characteristic All Patients (N = 93)
Chemotherapy
0 Regimens 77 (83)
1 Regimen 10 (11)
≥2 Regimens 6 (6)
Time since most recent therapy for thyroid cancer — mo**
Median 11.6
Range 1.2–367.2
Tumor genotyping — no. (%)††
Mutation in BRAF (V600E) 10 (30)
Mutation in HRAS (Q61R) 1 (3)
Mutation in KRAS (G12C) 1 (3)
Mutation in NRAS (Q61R and Q61K) 4 (12)
Mutation in RET 0
Mutation in PlK3CA 0
RET-PTC1 rearrangement 0
RET-PTC3 rearrangement 0
PAX8-PPARγ1 rearrangement 0
No mutation or rearrangement identified 17 (52)
* Race or ethnic group was determined from patients’ records.
† This category includes three patients with tumors that were classified histologically as a follicular variant of the papil-
lary subtype.
‡ This category includes three patients with an insular variant of the follicular histologic subtype and one patient with a 
poorly differentiated histologic subtype.
§ Data were available for 80 patients.
¶ ECOG denotes Eastern Cooperative Oncology Group. 
‖ Patients received subsequent thyrotropin-suppressive therapy or (less commonly) replacement therapy with levothy-
roxine.
** Data were available for 91 patients.
†† Data were available for 33 patients.
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typing, which are shown in detail in Table 3 in 
the Supplementary Appendix. Of 25 patients with 
papillary thyroid carcinoma, 10 had tumors car-
rying the mutant BRAF V600E oncogene, and 
4 had mutations in RAS genes (HRAS and KRAS 
in 1 patient each and NRAS in 2 patients).
Efficacy
The primary end point of a confirmed objective 
response was achieved in 13 patients (14%; 95% 
confidence interval [CI], 7.7 to 22.7), all of whom 
had partial responses; the median time to the re-
sponse was 15 weeks (95% CI, 8 to 27) (Table 2). 
Stable disease was observed in 62 patients (67%), 
with durable stable disease (i.e., disease that was 
stable for 24 weeks or more) in 33 patients (35%). 
Nine patients (10%) had unconfirmed partial re-
sponses that were classified as stable disease. 
Overall, 49% of the patients had either a con-
firmed partial response or durable stable disease. 
Disease progression was the best observed re-
sponse in seven patients (8%). In 69 patients 
(74%), tumor measurements decreased from the 
baseline measurements (Fig. 1).
Of the 13 patients with an objective response, 
4 had disease that subsequently progressed while 
the patients were taking the study medication. 
The Kaplan–Meier estimate of the median dura-
tion of a response was 32 weeks (the lower limit 
of the 95% CI was 24; the upper limit could not 
be estimated because of an insufficient number 
of events). The estimated median progression-free 
survival was 40 weeks (95% CI, 32 to 50) (Fig. 2A). 
The median overall survival was not estimable; the 
estimate of the survival rate at 12 months was 
73% (95% CI, 63 to 83) (Fig. 2B).
There was no significant difference in the rate 
of the objective response between patients with 
the papillary or follicular variant of papillary 
carcinoma (57 patients) and those with the fol-
licular or Hürthle-cell type (36 patients) (12% 
and 17%, respectively; P=0.56). We found no as-
sociation between the presence or absence of the 
BRAF V600E mutation (10 and 15 patients, re-
spectively) and the clinical outcome. Six of the 
10 patients whose tumor contained the BRAF mu-
tation had either a confirmed partial response or 
durable stable disease, as compared with 5 of the 
15 patients without the mutation (Table 3 in 
the Supplementary Appendix).
Safety
A total of 87 patients (94%) had at least one treat-
ment-related adverse event during the course of 
the study (Table 3). Twelve patients (13%) discon-
tinued treatment owing to adverse events. The 
most commonly reported events were diarrhea, 
hypertension, fatigue, and weight loss; patients 
with hypertension were treated with antihyperten-
sive medication, and those with diarrhea, fatigue, 
or weight loss received supportive care. Grade 3 
events were reported in 51 patients (55%); 5 pa-
tients had a total of eight treatment-related grade 
4 events (hypocalcemia in 2 patients and hyper-
uricemia, hypokalemia, cerebral hemorrhage, 
confusion, agitation, and oliguria in 1 patient 
each). There were two treatment-related deaths; 
both were due to pulmonary hemorrhage and oc-
curred in patients in whom the disease had pro-
gressed. Several treatment-related events of in-
terest (previously observed with anti-VEGF or 
anti-VEGF receptor therapies) were noted (Table 3). 
Increased thyrotropin concentrations, hypothy-
roidism, or both were reported in 22% of the pa-
tients. Five patients (5%) had cholecystitis (grade 2 
in three patients and grade 3 in two patients). 
Two patients had treatment-related cardiac disor-
ders; one had bradycardia, palpitations, and tachy-
cardia, and one had myocardial ischemia (grade 2 
in both patients).
Pharmacokinetics
Motesanib was rapidly absorbed, with a median 
time to the maximal plasma concentration (Cmax) 
of 1.0 hour; the terminal half-life was approxi-
mately 6.7 hours. The mean (±SD) motesanib Cmax 
value (787±526 ng per milliliter [2.10±1.41 μmol 
per liter]) and area under the plasma concentra-
tion–time curve (AUC0-24, 3.99±1.42 μg × hour 
per milliliter [10.7±3.79 μmol × hour per liter]) 
were similar to those observed for the 125-mg 
dose in another study of motesanib as monother-
apy for solid tumors.13 Between weeks 4 and 24, 
the median trough plasma concentration (Cmin), 
measured in 9 to 23 patients at different time 
points, ranged from 8.50 to 26.3 ng per milliliter 
(22.7 to 70.3 nmol per liter) and was consistently 
above the IC50 value (4 ng per milliliter [10 nmol 
per liter]) for inhibition of the proliferation 
of human umbilical-vein endothelial cells in 
 vitro.12
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Table 2. Tumor Response According to RECIST and Independent Review.*
Variable All Patients (N = 93)
Assessment of response — no. (%)
Complete response 0
Partial response 13 (14)
Stable disease 62 (67)
Unconfirmed partial response classified as stable disease† 9 (10)
Durable stable disease (≥24 wk) 33 (35)
Progressive disease 7 (8)
No data on response available‡ 11 (12)
Objective response — % (95% CI) 14 (7.7–22.7)
Clinical benefit — no. (%)§ 46 (49)
Time to tumor response — wk
Median 15 
95% CI 8−27
Duration of partial response 
Censored data — no./total no. (%)¶ 8/13 (62)
Patients who had a relapse — no./total no. (%) 5/13 (38)
Kaplan–Meier estimate of median duration — wk (95% CI) 32 (24–NE)
Progression-free survival 
Alive with no progression — no. (%) 43 (46)
Progression or death — no. (%) 50 (54)
Kaplan–Meier estimate of median progression-free survival — wk (95% CI) 40 (32–50)
Kaplan–Meier estimate of progression-free survival rate — % (95% CI)
Week 16 78 (69–87)
Week 32 60 (50–71)
Week 48 37 (24–50)
Overall survival
Patients who survived — no. (%) 66 (71)
Patients who died — no. (%) 27 (29)
Kaplan–Meier estimate of median overall survival — mo (95% CI) NE
Kaplan–Meier estimate of survival rate — % (95% CI)
Month 4 89 (82–95)
Month 8 82 (74–90)
Month 12 73 (63–83)
* NE denotes not estimable (insufficient number of events).
† Seven patients had a single assessment of partial response with a subsequent assessment of progressive disease or 
had no additional tumor assessment; two patients with follicular or Hürthle-cell carcinoma did not have the required 
bone scans to confirm partial response.
‡ No week 8 scans were available (scans were obtained before day 47 or no radiographic assessments were performed), 
available scans were not interpretable, or no baseline scans were available.
§ Clinical benefit was defined as either a confirmed partial response or durable stable disease.
¶ Data for patients with a confirmed objective response and no assessment of disease progression during the study are 
included as censored data at the time of the last disease assessment.
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Thyroglobulin Analyses
Of the 75 patients in whom thyroglobulin analy-
sis was performed, 61 (81%) had serum thyroglob-
ulin concentrations that decreased from baseline 
during the study. In 34 patients (45%) the decrease 
was 50% or more, and that decrease was sus-
tained for 24 weeks or more in 11 patients (15%). 
A correlation was observed between a decrease 
from baseline of 50% or more in thyroglobulin 
concentration and a decrease from baseline of 
30% or more in the sum of the longest diameter 
of target tumor lesions (Spearman’s rank correla-
tion coefficient, 0.472; P<0.001).
Discussion
The treatment for progressive, advanced or meta-
static differentiated thyroid cancer has been lim-
ited to surgery, radioiodine therapy, external-beam 
radiation therapy, or a combination of these 
treatments. In patients with radioiodine-resistant 
disease, cytotoxic chemotherapy yields low re-
sponse rates of short duration, is often associated 
with considerable toxicity, and does not prolong 
survival.15-17 Recently, angiogenesis has been ex-
plored as a target for the treatment of advanced 
thyroid cancer. A study of thalidomide, which has 
several actions, including the inhibition of angio-
genesis, showed that 5 of 28 patients with a va-
riety of thyroid cancers had unconfirmed par-
tial respons es on the basis of criteria other than 
RECIST.18
We found that 13 of 93 patients with progres-
sive, radioiodine-resistant, locally advanced or 
metastatic differentiated thyroid cancer who re-
ceived 125 mg of motesanib diphosphate once 
daily had a partial response. Of these 93 patients, 
87 had at least one adverse event, and 51 had a 
grade 3 adverse event. The response to motesanib 
diphosphate, which inhibits multiple signaling 
pathways that are involved in differentiated thy-
roid tumorigenesis, including VEGF and platelet-
derived growth-factor receptors,12 suggests that 
inhibiting angiogenesis in differentiated thyroid 
cancer may be clinically useful. Recent prelimi-
nary data suggest that other inhibitors of VEGF 
receptors have efficacy in advanced thyroid can-
cer.19,20 In a single-institution trial of sorafenib, 
the confirmed partial response rate among 58 
patients with metastatic papillary thyroid carci-
noma was 3%.20 In our study of 93 patients with 
progressive differentiated thyroid cancer, the pro-
portion of patients who had stable disease (67%), 
the proportion who had durable stable disease 
(35%) and the median progression-free survival 
(40 weeks [95% CI, 32 to 50]) all suggest clini-
cally meaningful tumor control. In contrast, no 
partial or complete responses were seen in a 
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Figure 1. Maximum Percent Change from Baseline in the Sum of the Longest Diameters (SLD) of Target Lesions.
The change from baseline in tumor measurement as assessed by an independent review is shown for 81 patients. 
Not shown are data for three patients with stable disease (only nontarget lesions at baseline according to an inde-
pendent review), one patient with progressive disease due to a new lesion (SLD unavailable), and eight patients with 
no radiographic assessments available (no information on disease response and no SLD measurements). In three of 
the patients with missing information on tumor response, SLD measurements were performed before week 8. An 
unconfirmed partial response was classified as stable disease in nine patients. One additional patient had more 
than a 30% decrease from baseline in SLD but had progression in a nontarget lesion. Target and nontarget lesions 
are defined according to the Response Evaluation Criteria in Solid Tumors (RECIST).14
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phase 2 study of gefitinib, an inhibitor of the 
epidermal growth factor receptor, among 18 pa-
tients with advanced differentiated thyroid can-
cer, and the progression-free survival time was 
only 3.7 months (95% CI, 1.8 to 5.7).21
Changes in the thyroglobulin concentration 
are used to monitor residual tumor volume, re-
current or metastatic tumor growth, or both in 
patients with differentiated thyroid cancer.22,23 
The decrease in serum thyroglobulin levels that 
we found in most patients and its correlation 
with the tumor response are consistent with the 
findings previously reported for radioiodine ther-
apy.24 The magnitude of this effect was probably 
underestimated because thyrotropin promotes 
thyroglobulin secretion, and treatment with 
motesanib diphosphate caused increased serum 
concentrations of thyrotropin.
We attempted to correlate the tumor genotype 
and clinical response in differentiated thyroid can-
cer, but the number of tumors available to be stud-
ied was too small to draw conclusions about an 
association of responsiveness with BRAF mutations 
that influence the VEGF-signaling pathway.25
Two adverse events related to motesanib 
diphosphate treatment are worth mentioning. 
Hypothyroidism, an increase in the thyrotropin 
concentration, or both occurred in 22% of the 
patients and have recently been reported during 
treatment with the multikinase inhibitors suni-
tinib,26 imatinib,27 and possibly sorafenib.28 In 
athyreotic patients (patients whose thyroids were 
surgically resected), motesanib diphosphate may 
induce alterations in the absorption or metabo-
lism of thyroxine instead of affecting thyroid hor-
mone synthesis, a mechanism that is implicated 
in sunitinib-induced hypothyroidism.26 Given these 
multiple effects on thyroid function, we suggest 
close monitoring of thyrotropin levels and ad-
justments in the dose of levothyroxine, as appro-
priate, in patients who are receiving multikinase 
inhibitors. In five patients in our study (5%), chole-
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Figure 2. Kaplan−Meier Analysis of Progression-free Survival and Overall Survival.
Panel A shows progression-free survival among all 93 patients who received at least one dose of motesanib diphos-
phate. Panel B shows overall survival among the same patients. Eight patients died during the course of the study, 
within 30 days after the last administration of motesanib diphosphate; 19 additional patients died during long-term 
follow-up. The I bars indicate 95% confidence intervals. C denotes censored observation.
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cystitis developed, a complication that has not 
previously been reported in association with anti-
angiogenic therapy. These five patients presented 
with classic symptoms (right-upper-quadrant pain 
and fever) and had a response to medical or sur-
gical treatment (or both), including cholecystec-
tomy. This incidence of cholecystitis is higher than 
expected on the basis of other studies of mote-
sanib diphosphate; however, the cause is unknown 
and the relation to motesanib diphosphate is un-
der investigation.
The key limitation of this trial was the lack of 
randomization with a control group. Because the 
study group specifically included patients with 
advanced differentiated thyroid cancer, tradition-
al comparator therapies, such as cytotoxic chemo-
therapy, were inappropriate owing to their inef-
fectiveness and toxicity. However, we believe that 
the large number of patients enrolled in this 
study allowed a reasonable estimate of clinical 
benefit.
In conclusion, motesanib diphosphate may be 
an effective treatment in some patients with pro-
gressive, metastatic, radioiodine-resistant differ-
entiated thyroid cancer. However, a broader ap-
plicability of treatment that inhibits angiogenesis 
Table 3. Treatment-Related Adverse Events and Related Adverse Events of Interest in the 93 Patients.
Event All Grades Grade 3 Grade 4 Grade 5
no. of patients (%)
All treatment-related adverse events
Adverse events 87 (94) 51 (55) 5 (5) 2 (2)
Serious adverse events 19 (20) 8 (9) 5 (5) 2 (2)
Treatment-related adverse events in ≥10% of pa-
tients
Diarrhea 55 (59) 12 (13) 0 0
Hypertension 52 (56) 23 (25) 0 0
Fatigue 43 (46) 4 (4) 0 0
Weight loss 37 (40) 5 (5) 0 0
Abdominal pain 28 (30) 5 (5) 0 0
Nausea 26 (28) 2 (2) 0 0
Anorexia 25 (27) 4 (4) 0 0
Headache 24 (26) 3 (3) 0 0
Dry mouth 13 (14) 0 0 0
Hypothyroidism 11 (12) 0 0 0
Vomiting 11 (12) 1 (1) 0 0
Increased thyrotropin 11 (12) 0 0 0
Asthenia 10 (11) 0 0 0
Arthralgia 9 (10) 1 (1) 0 0
Related adverse events of interest*
Hypothyroidism, increased thyrotropin,  
or both
20 (22) 0 0 0
Hemorrhage 13 (14) 1 (1) 1 (1) 2 (2)
Gallbladder toxicity† 12 (13) 2 (2) 0 0
Thromboembolic events 2 (2) 1 (1) 0 0
Cardiac disorders‡ 2 (2) 0 0 0
* Adverse events of interest are those previously observed with anti-VEGF or anti-VEGF receptor therapies.
† Gallbladder toxicity included biliary cholic, cholecystitis, acute cholecystitis, cholelithiasis, gallbladder enlargement, and 
gallbladder edema.
‡ Cardiac disorders included bradycardia, palpitations, and tachycardia (in one patient) and myocardial ischemia (in one).
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA STUDI DI TORINO on April 28, 2012. For personal use only. No other uses without permission. 
 Copyright © 2008 Massachusetts Medical Society. All rights reserved. 
Motesanib Diphosphate in differentiated Thyroid Cancer
n engl j med 359;1 www.nejm.org july 3, 2008 41
in thyroid cancer needs to be established in fur-
ther studies.
A ddendum
Therapy with the multikinase inhibitor sora fenib 
has been reported to yield a 26% partial response 
rate in patients with metastatic differentiated thy-
roid carcinoma.29
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